Aethlon Medical’s (AEMD) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $7.00 target price on the medical equipment provider’s stock.

Separately, StockNews.com raised shares of Aethlon Medical to a “sell” rating in a research note on Wednesday, February 19th.

Aethlon Medical Stock Down 5.5 %

NASDAQ:AEMD opened at $0.41 on Monday. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.85. The stock’s fifty day moving average is $0.65 and its two-hundred day moving average is $0.50. The stock has a market capitalization of $5.96 million, a price-to-earnings ratio of -0.26 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.09. On average, sell-side analysts expect that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aethlon Medical

Large investors have recently modified their holdings of the stock. Boothbay Fund Management LLC acquired a new position in Aethlon Medical during the 4th quarter worth $186,000. Virtu Financial LLC acquired a new stake in Aethlon Medical in the 4th quarter valued at about $81,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at about $31,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth about $26,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical during the fourth quarter worth approximately $25,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.